Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma

Ma, Li; Yue, Wentao; Teng, Yuee; Zhang, Lina; Gu, Meng; Wang, Yue

doi:10.1155/2013/935943

Cited by 23 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Interestingly, several other studies have also reported the specificity of AABs to be generally high. 13,[25][26][27] Consistent with these observations, we found a specificity of around 90% with our 7-AABs panel in this multicenter prospective study involving 2008 participants irrespective of the histological types and clinical stages, suggesting that this AAB panel is highly specific, even in the early stages of lung cancer.…”

Section: Discussionsupporting

confidence: 83%

Early detection of lung cancer by using an autoantibody panel in Chinese population

et al. 2017

View full text Add to dashboard Cite

We have previously identified a panel of autoantibodies (AABs), including p53, GAGE7, PGP9.5, CAGE, MAGEA1, SOX2 and GBU4-5, that was helpful in the early diagnosis of lung cancer. This large-scale, multicenter study was undertaken to validate the clinical value of this 7-AABs panel for early detection of lung cancer in a Chinese population. Two independent sets of plasma samples from 2308 participants were available for the assay of AABs (training set = 300; validation set = 2008). The concentrations of AABs were quantitated by enzyme-linked immunosorbent assay (ELISA), and the optimal cutoff value for each AAB was determined in the training set and then applied in the validation set. The value of the 7-AABs panel for the early detection of lung cancer was assessed in 540 patients who presented with ground-glass nodules (GGNs) and/or solid nodules. In the validation set, the sensitivity and specificity of the 7-AABs panel were 61% and 90%, respectively. For stage I and stage II non-small cell lung cancer (NSCLC), the sensitivity of the 7-AABs panel was 62% and 59%, respectively, and for limited stage small cell lung cancer (SCLC) it was 59%; these sensitivity values were considerably higher than for traditional biomarkers (including CEA, NSE and CYFRA21-1). Importantly, the combination of the 7-AABs panel and low-dose computed tomography (CT) scanning significantly improved the diagnostic yield in patients presenting with GGNs and/or solid nodules. In conclusion, our 7-AABs panel has clinical value for early detection of lung cancer, including early-stage lung cancer presenting as GGNs.

show abstract

Section: Discussionsupporting

confidence: 83%

Early detection of lung cancer by using an autoantibody panel in Chinese population

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated the presence of significant levels of autoantibodies in lung cancer patients as compared to healthy donors (33,96,. Circulating autoantibodies to individual p53, annexin A1-derived peptide antigens, CCNY, IGFBP-2, p16, chromogranin A-derived peptides were significantly higher in cancer patients than control subjects (243)(244)(245)(246)(247)(248)(249)(250)(251)(252). Autontibodies to two or more antigens including HuC/HuD, SMOX/ NOLC1/MALAT1 and HMMR, NY-ESO-1/XAGE-1/ ADAM29, and MAGEC1, p53/NY-ESO-1/CAGE, GBU4-5/Annexin 1 and SOX2, 14-3-3ζ/-c-Myc/ MDM2/Nucleophosmin 1/p16/p53 and cyclin-B1, p62/BIRC/Livin-1/p53/Peroxiredoxin/NY-ESO-1 and Ubiquitin, and several other antigens combination were analyzed for improving the sensitivity and specificity of the assays for discriminating cancer patients from healthy donors (33,96,(253)(254)(255)(256)(257)(258)(259)(260).…”

Section: Role Of Autoantibodies To Self Antigens As Biomarkers For Camentioning

confidence: 99%

“…Autontibodies to two or more antigens including HuC/HuD, SMOX/ NOLC1/MALAT1 and HMMR, NY-ESO-1/XAGE-1/ ADAM29, and MAGEC1, p53/NY-ESO-1/CAGE, GBU4-5/Annexin 1 and SOX2, 14-3-3ζ/-c-Myc/ MDM2/Nucleophosmin 1/p16/p53 and cyclin-B1, p62/BIRC/Livin-1/p53/Peroxiredoxin/NY-ESO-1 and Ubiquitin, and several other antigens combination were analyzed for improving the sensitivity and specificity of the assays for discriminating cancer patients from healthy donors (33,96,(253)(254)(255)(256)(257)(258)(259)(260). In addition, autoantibodies to p16, NY-ESO-1, XAGE-1, ADAM29, and MAGEC1 were associated with advanced disease stages, those to c-Myc were related to shortened DFS and those to p53 or to CCNY were linked to shorter survival or worse prognosis (33,243,244,249,251,254,261,262). Conversely, ANAs were linked to a better patients survival (263).…”

Section: Role Of Autoantibodies To Self Antigens As Biomarkers For Camentioning

confidence: 99%

The crossroads between cancer immunity and autoimmunity antibodies to self antigens

et al. 2017

View full text Add to dashboard Cite

The production of autoantibodies to self antigens is dependent on the failure of immune tolerance. Cancer cells express antigens which elicit a spontaneous immune response in cancer patients. The repertoire of autoantibodies found in cancer patients partly covers that of patients with autoimmune diseases. Biological activities of autoantibodies to self antigens may induce paraneoplastic syndromes which reflect the attempt of cancer patients to counteract tumor growth. Autoantibodies with similar specificities may have different effects in cancer and autoimmune disease patients due to different immunological microenvironments. Tregs dysfunction has been observed in patients with paraneoplastic syndromes and/or with autoimmune diseases, while the increase of Tregs has been associated with poor cancer patients prognosis. Novel therapies have employed antibodies against Tregs immune-checkpoint receptors with the aim to boost immune response in cancer patients. The presence of autoantibodies to tumors antigens has also been investigated as a marker for cancer detection and cancer patients prognosis. This report reviews the current knowledge on the analysis and meaning of autoantibodies to self antigens detected in cancer and autoimmune disease patients.

show abstract

“…High levels of autoantibodies were detected at 5 years before patients developed lung cancer 7. Several studies have demonstrated that circulating autoantibodies banding to tumor-associated antigens may have the potential to serve as biomarkers in the diagnosis and prognosis of malignant diseases 8–10. However, the efforts to diagnose cancer and evaluate the prognosis by using autoantibodies were less successful.…”

Section: Introductionmentioning

confidence: 99%

Combined detection of dickkopf-1 subtype classification autoantibodies as biomarkers for the diagnosis and prognosis of non-small cell lung cancer

Shen¹,

Wu²,

Tan³

et al. 2017

OTT

Self Cite

View full text Add to dashboard Cite

PurposeThis study aims to identify the clinical significance of serum autoantibodies against dickkopf-1 (DKK1) and evaluate their feasibility in the immunodiagnosis and prognosis of non-small cell lung cancer (NSCLC).Experimental designEpitope mapping by peptide microarray-based serum screening of NSCLC patients (n=72) and healthy controls (n=16) was performed. Indirect ELISA with peptides was used to measure the serum levels of autoantibodies in 206 NSCLC patients and 99 healthy controls. A 3-year follow-up was monitored to evaluate the correlation between serological levels of autoantibodies and overall survival (OS) and progression-free survival (PFS).ResultsFour highly reactive epitopes were identified, which included peptides 67–84 (Pep A), 37–54 (Pep B), 145–156 (Pep C) and 247–261 (Pep D). The autoantibodies levels were considerably higher in sera of NSCLC patients compared with controls (P<0.001), and a highly significant correlation with distant metastases was observed (Pep A: P=0.09, Pep B: P<0.01, Pep C: P<0.01 and Pep D: P<0.01). High levels of antibody subtype to Pep B were remarkably associated with better OS (P=0.004) and PFS (P=0.006). Subsequent Cox regression analysis disclosed that antibody to Pep B was an independent prognostic factor for NSCLC (OS: P=0.008, HR =0.435, 95% CI 0.236–0.802; PFS: P=0.032, HR =0.533, 95% CI 0.322–0.950).ConclusionIdentified linear epitopes of antigens by peptide microarray are easily available, and subtype classification of DKK1 autoantibodies as novel biomarkers for the diagnosis and prognosis of NSCLC. Our results also highlight the antibody subtype to Pep B as the most valuable biomarker for favorable prognosis of NSCLC.

show abstract

Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma

Cited by 23 publications

References 26 publications

Early detection of lung cancer by using an autoantibody panel in Chinese population

Early detection of lung cancer by using an autoantibody panel in Chinese population

The crossroads between cancer immunity and autoimmunity antibodies to self antigens

Combined detection of dickkopf-1 subtype classification autoantibodies as biomarkers for the diagnosis and prognosis of non-small cell lung cancer

Contact Info

Product

Resources

About